Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma

NCT03586999 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03586999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03586999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Lead sponsor
University of Colorado, Denver
Phase
Phase 1/2
Overall status
Completed
Start date
November 7, 2018
Completion date
September 20, 2022
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma